ケーススタディー
Built on a legacy of innovation, the Daré Bioscience Intelligent Drug Delivery System (IDDS) aims to redefine patient care and set a new standard for the future of drug delivery.
The first-of-its-kind platform seamlessly integrates precision drug delivery, implantable electronics, secure connectivity and patient control – all in a single device capable of storing up to 10 years of medication for certain indications. By giving patients the power to manage their own treatment with an intelligent, adaptable system, this innovative platform could mark the beginning of a bold new era for patient-centred, technology-driven healthcare.
Groundbreaking innovation answers shifting patient and market needs
Daré’s groundbreaking IDDS is emerging at an opportune moment. Patients are increasingly seeking solutions that adapt to their lives rather than adapting themselves to onerous treatment regimens. This demand comes as healthcare and drug delivery sectors strive to take strain off overstretched clinics and bring care directly into patients’ homes.
Recent industry advances in sensing, connectivity and data analytics were the final pieces needed to advance this innovation towards the clinic, signalling Daré to join forces with us to develop an ambitious and truly novel solution. As the deep tech powerhouse of Capgemini, this is where CC thrives – at the intersection of technology, security and regulation, where solutions must be invented rather than adapted.
Designed to provide a revolutionary new model of care where treatment can be monitored, adjusted and paused remotely, this innovation could offer patients and clinics more than just convenience – but also privacy, accessibility and freedom, representing a meaningful shift in how treatment is managed for both patients and clinics.
“Implantables have been around for a while – but with the Daré IDDS technology, the electro-mechanical aspect offers a whole new range of possibilities, for example in terms of being able to turn dosing on and off, combined with the communication capabilities…it really is a new mode of treatment.”
A cross-therapeutic drug delivery platform that puts the patient at the centre
Unlike traditional drug delivery devices, which are typically limited to one drug, dose or indication, the Daré IDDS platform technology could store and deliver a variety of medications over extended periods. Supporting injection-like doses, continuous release or synchronised dosing based on patient physiology or disease progression, its real-time connectivity would allow patients and clinicians to remotely monitor and adjust therapy.
As a result, this single implanted device platform could deliver therapies across diverse patient populations, enabling long-term, personalised care. For example, a breast cancer survivor could replace 60+ monthly clinic visits over 5 years with just one device. In fertility treatment, the IDDS’ independent drug reservoirs could offer precise, timed delivery of different therapies from a single device replacing multiple injections, while for contraception, patients could store up to 10 years of medication and control their reproductive journeys according to their family planning needs.
For chronic metabolic conditions requiring frequent injections, long-term home-based treatment reduces the burden of care, for example for Parkinson’s patients, where automated doses overnight could prevent “off” episodes before morning doses take effect.
The list goes on, showing how the Daré IDDS platform could be the key to offering patients the freedom and flexibility to manage ongoing care without interrupting daily life, enhancing both their quality of life and relieving caregiver pressures.
“Daré is far more mature in their technology compared to anybody else on the market right now. You don’t see this level of complexity that often, especially in the drug delivery space. This is really cutting edge.”
Deep tech at the intersection of biology and engineering
At the core of the Daré IDDS lies a groundbreaking fusion of advanced technologies rarely seen together in a single medical device. Built around micro-electromechanical systems (MEMS), the device features independent drug reservoirs, each capable of releasing precise doses electronically and on demand.
Designed as a connected system, the platform is able to transmit device performance and function data while still implanted. This data could be wirelessly transmitted to clinicians, enabling them to monitor the patient’s treatment, adjust therapy parameters or pause treatment when necessary. The system also promises a level of control never before seen in implantable drug delivery, offering unparalleled autonomy.
Achieving this feat requires ultra-reliable, miniaturised wireless communication systems that operate within what is effectively a hostile environment: the human body. Electronics must survive for up to a decade, all while maintaining performance to ensure patient safety. At the same time, data must be transmitted securely, safeguarding patient privacy and preventing unauthorised access or dose manipulation.
This is the kind of cutting-edge deep tech innovation that CC is known for – bringing together implantable electronics, advanced sensing, wireless connectivity, data services, software safety, cybersecurity, and pharmaceuticals to create a truly unique, first-of-its-kind solution.
“Our partnership with Cambridge Consultants really allowed us to take the IDDS platform and the concept to the next level… I really feel that without their deep technical expertise and guidance we would not be at the point we are today with this product.”
A multidisciplinary technical challenge
5Gとワイヤレスコネクティビティ
最先端の情報処理
DX
医療機器
製薬
A long-term partnership founded on innovation and a shared vision
The ambition and complexity of the IDDS concept called for a technology partner with deep expertise in active implantable medical devices, safety-critical software and connected health systems, making CC a natural fit. This project also perfectly aligned with CC’s deep tech strategy of creating bold, new-to-the-world technology that offers a first-mover advantage.
But the roots of Daré and CC’s strategic partnership go back much further than the IDDS. CC’s Boston office worked with the original technology concept originating from Bob Langer’s lab at MIT nearly 20 years ago during the earliest days of its development. The modern phase of our collaboration began in 2018 as Daré sought to transform a clinical concept into the scalable, regulatory-ready IDDS, bringing our collaboration on this technology full circle.
As the partnership and project grew, our role expanded beyond design support to include early-stage fundraising assistance, grant-related technical development and sustained R&D collaboration. Ultimately, the relationship has evolved into a long-term partnership built on resilience, a unified one team mentality and a shared mission to improve patient care.
“In the case of the Daré IDDS technology, we partnered with Cambridge Consultants to help turn this innovative benchtop concept into something that can be commercially scaled and deliver on all objectives in terms of size, comfort, ease of use and drug delivery. Pulling it all together is where we really looked to our relationship with CC.”
A drug delivery platform poised for global impact
This groundbreaking cross-therapeutic drug delivery platform helps to position Daré as a true pioneer in intelligent implantable drug delivery. This goes beyond simply an incremental upgrade on existing drug delivery systems – this promises to be something entirely new: a novel, innovative mode of treatment that would stands alone in the drug delivery market.
But at the heart of this project has always been the patients, and they are the ones who could one day experience the greatest benefits. By combining continuous treatment with remote clinician monitoring and patient control, the Daré IDDS aims to empower users in ways existing methods cannot – especially for those in rural and resource-limited areas with long-term treatment needs.
With potential applications across women’s health, oncology, neurology and beyond, Daré Bioscience and CC are paving the way for a future where intelligent remote therapy is the norm, transforming markets, redefining patient care and improving lives worldwide.
